Extending Progression-Free Survival in Ovarian Cancer With Pazopanib

September 25, 2013
Andreas du Bois, MD

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

This phase III, randomized, multicenter clinical trial (AGO-OVAR16) was open to patients who had already received primary treatment for advanced ovarian cancer and had not progressed until the end of treatment, du Bois says. The patients were randomized to receive either pazopanib (for 2 years) or placebo.

Clinical Pearls

The trial found that pazopanib (Votrient), following initial successful chemotherapy, extended disease-free survival by an average of 5.6 months compared with a placebo in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  • Patients who had primary treatment of advanced ovarian cancer were included in this trial
  • Patients had not progressed until end of treatment and then were randomized to receive pazopanib and placebo
  • Pazopanib extended disease-free survival by an average of 5.6 months compared with a placebo